ZA200906374B - C5 antigens and uses thereof - Google Patents

C5 antigens and uses thereof

Info

Publication number
ZA200906374B
ZA200906374B ZA200906374A ZA200906374A ZA200906374B ZA 200906374 B ZA200906374 B ZA 200906374B ZA 200906374 A ZA200906374 A ZA 200906374A ZA 200906374 A ZA200906374 A ZA 200906374A ZA 200906374 B ZA200906374 B ZA 200906374B
Authority
ZA
South Africa
Prior art keywords
antigens
Prior art date
Application number
ZA200906374A
Other languages
English (en)
Inventor
Braydon Charles Guild
Mark Taylor Keating
Mariusz Milik
Dmitri Mikhailov
Michael Roguska
Igor Splawski
Kehao Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200906374B publication Critical patent/ZA200906374B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
ZA200906374A 2007-03-22 2009-09-14 C5 antigens and uses thereof ZA200906374B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89640807P 2007-03-22 2007-03-22

Publications (1)

Publication Number Publication Date
ZA200906374B true ZA200906374B (en) 2010-05-26

Family

ID=39672693

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200906374A ZA200906374B (en) 2007-03-22 2009-09-14 C5 antigens and uses thereof

Country Status (17)

Country Link
US (1) US20100166748A1 (xx)
EP (1) EP2129681A2 (xx)
JP (1) JP2010521194A (xx)
KR (1) KR20100015773A (xx)
CN (1) CN101679486A (xx)
AU (1) AU2008228247A1 (xx)
BR (1) BRPI0809105A2 (xx)
CA (1) CA2680760A1 (xx)
CL (1) CL2008000803A1 (xx)
EA (1) EA200901211A1 (xx)
IL (1) IL201020A0 (xx)
MA (1) MA31351B1 (xx)
MX (1) MX2009010181A (xx)
TN (1) TN2009000381A1 (xx)
TW (1) TW200848076A (xx)
WO (1) WO2008113834A2 (xx)
ZA (1) ZA200906374B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
PT3028716T (pt) 2006-10-10 2020-11-23 Regenesance B V Inibição do complemento para regeneração nervosa melhorada
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
KR20220162801A (ko) 2008-04-11 2022-12-08 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
CN102597005A (zh) * 2009-06-23 2012-07-18 阿雷克森制药公司 与补体蛋白质结合的双特异性抗体
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
ES2606134T3 (es) 2011-07-29 2017-03-22 Andritz S.A.S. Centrifugador y miembro de orificio de descarga de centrifugador para reducción de potencia
EP2583957A1 (de) 2011-10-18 2013-04-24 LANXESS Deutschland GmbH Lineare Butene aus Isobutanol
DK2817329T3 (en) * 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polypeptides Binding to Human Complement Component C5.
CA2866232A1 (en) * 2012-05-25 2013-11-28 Novartis Ag Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
RU2018125515A (ru) * 2013-01-31 2018-10-29 СЕУЛ НЭШНЛ ЮНИВЕРСИТИ Ар энд ДиБи ФАУНДЕЙШН Антитело против c5 и способ предупреждения и лечения обусловленных комплементом заболеваний
AU2014244116B9 (en) 2013-03-14 2020-08-13 Alnylam Pharmaceuticals, Inc. Complement component C5 iRNA compositions and methods of use thereof
EP3628680B1 (en) 2014-06-12 2021-09-08 RA Pharmaceuticals, Inc. Modulation of complement activity
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
US11031102B2 (en) 2014-11-17 2021-06-08 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
KR102515796B1 (ko) * 2014-12-19 2023-03-30 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 그의 사용 방법
RS62630B9 (sr) 2015-01-28 2022-04-29 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
EP3389692B1 (en) 2015-12-16 2020-03-04 RA Pharmaceuticals, Inc. Modulators of complement activity
PE20181402A1 (es) * 2015-12-18 2018-09-07 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y metodos de uso
WO2017212375A1 (en) * 2016-06-07 2017-12-14 Novartis Ag Anti-c5 antibody for treating patients with complement c5 polymorphism
MX2018015030A (es) * 2016-06-17 2019-04-22 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y metodos de uso.
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
US20190328854A1 (en) * 2016-08-29 2019-10-31 The Cleveland Clinic Foundation C5 immunization for autologous anti-c5 antibody production
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
CN110603054B (zh) * 2017-03-06 2024-05-10 宾夕法尼亚大学理事会 抗c5抗体及其用途
PL3612208T3 (pl) 2017-04-21 2023-07-24 Volution Immuno Pharmaceuticals Sa Coversin do leczenia autoimmunologicznych chorób pęcherzowych
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
JP4290564B2 (ja) * 2002-03-19 2009-07-08 チルドレンズ ホスピタル メディカル センター Ｃ５ａアナフィラトキシンの突然変異タンパク質、このような突然変異タンパク質をコードする核酸分子ならびにＣ５ａアナフィラトキシンの突然変異タンパク質の医薬的使用
DK2860251T3 (en) * 2004-02-12 2018-06-06 Archemix Llc APTAPMER PHARMACEUTICALS USEFUL IN TREATMENT OF COMPLEMENT-RELATED DISEASES
NZ567483A (en) * 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases

Also Published As

Publication number Publication date
WO2008113834A3 (en) 2009-03-05
BRPI0809105A2 (pt) 2019-09-10
MX2009010181A (es) 2009-12-04
TN2009000381A1 (en) 2010-12-31
MA31351B1 (fr) 2010-05-03
WO2008113834A2 (en) 2008-09-25
IL201020A0 (en) 2010-05-17
CA2680760A1 (en) 2008-09-25
JP2010521194A (ja) 2010-06-24
EA200901211A1 (ru) 2010-04-30
TW200848076A (en) 2008-12-16
CL2008000803A1 (es) 2008-10-03
EP2129681A2 (en) 2009-12-09
US20100166748A1 (en) 2010-07-01
CN101679486A (zh) 2010-03-24
AU2008228247A1 (en) 2008-09-25
KR20100015773A (ko) 2010-02-12

Similar Documents

Publication Publication Date Title
ZA200906374B (en) C5 antigens and uses thereof
SI2099826T1 (sl) Anti-beta-amiloidno protitelo in njegova uporaba
HK1142341A1 (en) Anti-hepcidin antibodies and uses thereof
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
EP2236604A4 (en) ANTI-NR10 ANTIBODIES AND USE THEREOF
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
HK1199041A1 (en) Sp35 antibodies and uses thereof sp35
IL216731A (en) And antibodies against p95 – her2 and their uses
HK1138771A1 (en) Antibodies against erbb3 and uses thereof
IL195658A0 (en) Anti-nkg2a antibodies and uses thereof
ZA200900351B (en) Prlr-specific antibody and uses thereof
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
IL236237A (en) Tmem154 antibodies and their segments and uses
HK1203206A1 (en) Antibody and use thereof
EP2193144A4 (en) ANTIBODIES TO FLAGELLIN AND APPLICATIONS THEREOF
EP2379106A4 (en) ANTIGENS OF CHLAMYDIAS AND USES THEREOF
EP2388320A4 (en) ANTI-HS6ST2 ANTIBODIES AND USE THEREOF
GB0812277D0 (en) Antibody and uses thereof
GB0707069D0 (en) Methods and uses
ZA200905136B (en) Anti-robo4 antibodies and uses therefor
GB0707609D0 (en) Methods and uses
GB0722451D0 (en) Methods and uses